THALES/NEURAL-LABS
13.3.2024 09:01:27 CET | Business Wire | Press release
Thales, a global leader in Software Monetization and Licensing, has expanded its partnership with Neural Labs, a company which provides video analysis for Smart Cities and AI-based Intelligent Transportation Systems (ITS), to enable secure, efficient, and practical solutions for vehicle access control and logistical planning.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240313492188/en/
© Thales
Thales’s Sentinel platform provides services for software licensing, entitlement management, delivery, and protection – helping Neural Labs to quickly and efficiently automate the creation and issuance of licenses. As a result, Neural Labs was able to reduce costs and focus more on its customers, as well as the value of its software against competitors.
The relationship between Thales and Neural Labs initially started over two decades ago when Neural Labs selected Sentinel for software protection. Since then, the company has moved into a new era of digital transformation and adopted Thales Sentinel Cloud Licensing to manage its SaaS offering.
With this latest licensing iteration, Neural Labs can maximise SaaS capabilities to deploy and update licenses from any location for their entire product portfolio and growing sales teams. This partnership expansion is therefore crucial for the organisation to achieve its growth ambitions in an increasingly connected world.
Over the last three years, Neural Labs increased its revenue by nearly 25%, with Thales Sentinel playing its part by helping to reduce revenue leakage from unauthorized software use.
“We always knew that we needed to protect our software and futureproof our business. Thales has been there with us since the very beginning to help us to avoid software piracy and make the most of every market opportunity. Now, we’re working with the team even more closely to prepare our software so that 100% will be offered on the cloud. The expansion of this partnership will help us to scale with the flexible and practical solutions, and our longstanding relationship means we can move forward with full trust.” Elias Varcarcel, CEO, Neural Labs
“For over 20 years, our team has provided the technical support to help Neural Labs on its mission to make cities, towns and the road network safer, smarter and more efficient. We’re incredibly proud that Neural Lab’s confidence in our platform and services has allowed them to grow exponentially. We’re now looking ahead to the next stage – full digital transformation backed by flexible and scalable solutions.” Damien Bullot, Vice President, Software Monetization, Thales
About Neural Labs
Neural Labs has more than 20 years of experience in the development of specialized software based on reading license plates and video analytics to revolutionize various sectors such as Smart Cities, Mobility, Security, Intelligent Transport Systems (ITS), vehicle traffic management, infractions control, logistics, and vehicular access. This remarkable array of capabilities stands as a testament to Neural Labs' substantial commitment to Research and Development.
The solutions crafted by Neural Labs go above and beyond, demonstrating excellence in reading and identifying vehicle license plates (ANPR or LPR) and ISO6346 codes of transport containers (ACCR).
Neural Labs is dedicated to designing solutions that simplify the lives of its clients, transforming their environments into safer and more efficient spaces.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.
Thales has 81,000* employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.
* These figures exclude the ground transportation business, which is being divested
PLEASE VISIT
Thales Group
Security
@Thalesgroup
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240313492188/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom